CY1112014T1 - Συνθεσεις αντιβακτηριακων εμβολιων - Google Patents

Συνθεσεις αντιβακτηριακων εμβολιων

Info

Publication number
CY1112014T1
CY1112014T1 CY20111100401T CY111100401T CY1112014T1 CY 1112014 T1 CY1112014 T1 CY 1112014T1 CY 20111100401 T CY20111100401 T CY 20111100401T CY 111100401 T CY111100401 T CY 111100401T CY 1112014 T1 CY1112014 T1 CY 1112014T1
Authority
CY
Cyprus
Prior art keywords
vaccine compositions
antibacterial vaccine
gram
negative bacterial
virulence genes
Prior art date
Application number
CY20111100401T
Other languages
English (en)
Inventor
David E Lowery
Troy E Fuller
Michael J Kennedy
Original Assignee
Pharmacia & Upjohn Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company Llc filed Critical Pharmacia & Upjohn Company Llc
Publication of CY1112014T1 publication Critical patent/CY1112014T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Ταυτοποιούνται γονίδια λοιμογονικότητας βακτηρίων αρνητικών κατά Gram, καθιστώντας έτσι δυνατή την ταυτοποίηση πρωτότυπων αντιβακτηριακών παραγόντων που στοχεύουν αυτά τα γονίδια λοιμογονικότητας και τα προϊόντα τους, και την παροχή πρωτότυπων μεταλλαγμάτων βακτηρίων αρνητικών κατά Gram που είναι χρήσιμα σε εμβόλια.
CY20111100401T 2001-03-15 2011-04-18 Συνθεσεις αντιβακτηριακων εμβολιων CY1112014T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/809,665 US6790950B2 (en) 1999-04-09 2001-03-15 Anti-bacterial vaccine compositions
EP02705915A EP1368456B1 (en) 2001-03-15 2002-01-17 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
CY1112014T1 true CY1112014T1 (el) 2015-11-04

Family

ID=25201919

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100401T CY1112014T1 (el) 2001-03-15 2011-04-18 Συνθεσεις αντιβακτηριακων εμβολιων

Country Status (18)

Country Link
US (2) US6790950B2 (el)
EP (1) EP1368456B1 (el)
JP (2) JP2005502315A (el)
AR (2) AR035745A1 (el)
AT (1) ATE500316T1 (el)
AU (1) AU2002240033B2 (el)
CA (2) CA2438315C (el)
CY (1) CY1112014T1 (el)
DE (1) DE60239318D1 (el)
DK (1) DK1368456T3 (el)
ES (1) ES2362041T3 (el)
MX (1) MXPA03008296A (el)
NZ (1) NZ528208A (el)
PE (1) PE20021008A1 (el)
PT (1) PT1368456E (el)
SI (1) SI1368456T1 (el)
TW (4) TWI335935B (el)
WO (1) WO2002075507A2 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455323B1 (en) * 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
JP4892134B2 (ja) * 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US7449178B2 (en) * 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
US7794734B2 (en) * 2002-10-30 2010-09-14 The Board Of Regents For Oklahoma State University Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2387827T3 (es) * 2006-10-05 2012-10-02 New York Blood Center, Inc. Péptidos antivirales helicoidales, de pequeño tamaño, terapéuticos estabilizados
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
CA2729818A1 (en) * 2008-07-03 2010-01-07 Biotechnology Research And Development Corporation Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
ES2824402T3 (es) * 2013-11-01 2021-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
ES2131069T3 (es) 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.
US5840312A (en) 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
JPH08503136A (ja) 1992-11-06 1996-04-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
AU1662595A (en) 1994-01-28 1995-08-15 Herbert Altmann Method of determining the activity of a regulatory factor, and use of the method
HUT76975A (hu) 1994-12-09 1998-01-28 Imperial College Innovations Limited Eljárás gének azonosítására
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
DK0939830T3 (da) * 1996-09-06 2009-04-06 Peter Ruhdal Jensen Fremgangsmåde til forbedring af produktionen af et önsket produkt fra en celle
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
JP4892134B2 (ja) 1999-04-09 2012-03-07 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗菌ワクチン組成物
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2001004347A1 (en) * 1999-07-12 2001-01-18 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase
US20030180330A1 (en) * 2000-04-27 2003-09-25 Meyer Thomas F Method for identifying helicobacter antigens

Also Published As

Publication number Publication date
US7476391B2 (en) 2009-01-13
US20050003512A1 (en) 2005-01-06
CA2852293A1 (en) 2002-09-26
EP1368456B1 (en) 2011-03-02
AR071888A2 (es) 2010-07-21
PE20021008A1 (es) 2002-11-13
AU2002240033B2 (en) 2007-11-08
DE60239318D1 (de) 2011-04-14
TWI328035B (en) 2010-08-01
PT1368456E (pt) 2011-06-01
JP2011097938A (ja) 2011-05-19
TW201040262A (en) 2010-11-16
TWI334884B (en) 2010-12-21
MXPA03008296A (es) 2007-05-28
WO2002075507B1 (en) 2003-12-11
TW200916577A (en) 2009-04-16
TWI335934B (en) 2011-01-11
US20040110268A1 (en) 2004-06-10
WO2002075507A2 (en) 2002-09-26
TWI335935B (en) 2011-01-11
JP2005502315A (ja) 2005-01-27
ATE500316T1 (de) 2011-03-15
CA2438315A1 (en) 2002-09-26
TW201040261A (en) 2010-11-16
EP1368456A2 (en) 2003-12-10
WO2002075507A3 (en) 2003-09-12
NZ528208A (en) 2008-04-30
CA2438315C (en) 2014-09-02
ES2362041T3 (es) 2011-06-27
DK1368456T3 (da) 2011-05-23
SI1368456T1 (sl) 2011-06-30
AR035745A1 (es) 2004-07-07
US6790950B2 (en) 2004-09-14

Similar Documents

Publication Publication Date Title
CY1112014T1 (el) Συνθεσεις αντιβακτηριακων εμβολιων
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
ATE485056T1 (de) Verbesserte impfstoffe
CY1106133T1 (el) Αγωνιστες υποδοχεα 2 παραγοντα απελευθερωσης κορτικοτροπινης
MY125202A (en) Vaccine
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DK1103564T3 (da) Cancerantigener baseret på tumorsuppressorgen WT1-produkt
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
CY1112871T1 (el) Μεθοδος κι ενδιαμεσες ενωσεις
DE60036698D1 (de) Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
WO2000061724A3 (en) Anti-bacterial vaccine compositions
ATE355104T1 (de) Haarbehandlungsmittel
SG167667A1 (en) Nucleic acid compositions for stimulating immune responses
WO1999001473A3 (en) Anti-bacterial methods and materials
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
NO20013102D0 (no) Gener, proteiner og deres anvendelse
PL372769A1 (en) Cyanoguanidine prodrugs
ATE515270T1 (de) Phep, eine aminosäurepermease von staphylococcus aureus
DE60226057D1 (de) Geflügelkrankheit verursachendes bakterium und daraus stammender impfstoff
DK1615656T3 (da) Immunmodulerende produkt opnået ud fra en Bifidobacterium-kultur og præparater indeholdende samme